Analyst predicts more Bavarian vaccine orders in Europe in light of monkeypox outbreak

As the EMA assesses the Danish firm’s smallpox vaccine within the monkeypox indication, a Sydbank analyst believes more orders are on the horizon.

Photo: Dado Ruvic/REUTERS / X02714

Following last week’s news that the European Medicines Agency (EMA) has initiated a risk/benefit analysis of using Danish biotech firm Bavarian Nordic’s smallpox vaccine against monkeypox, there could be more orders on the way than the firm has accounted for in its current 2022 guidance, says Senior Equity Analyst at Sydbank Søren Løntoft Hansen.

Løntoft Hansen’s analysis comes prior to the announcement of a shared European purchase of various vaccines and treatments for monkeypox.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs